NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements
Report Details Promise of Adaptive Cancer Immunotherapy in Treating Highly Malignant Brain TumorsRecent Achievements for Glioblastoma/Brain Tumor Treatment to be Addressed in Upcoming Presentation at World Orphan Drug CongressCLEVELAND, OH / ACCESSWIRE / May 11, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that Dr. Christopher Wheeler, Ph.D., President,...
Read more








